Payment overview · 2025
General Payments
$997.17
70 reported records · 13 companies
Healthcare provider profile · identity verified
Noam Zeffren
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · BAYONNE, NJ · NPI 1700373750
Verified facts
What the public records show
CMS Open Payments records show Noam Zeffren received $997.17 in general payments during 2025 across 70 reported records.
Sumitomo Pharma America, Inc. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $215.95 | 21.7% | 32 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $209.55 | 21.0% | 8 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $144.98 | 14.5% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $92.49 | 9.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $80.82 | 8.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $75.11 | 7.5% | 4 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $44.54 | 4.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.16 | 3.5% | 2 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $31.61 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.74 | 1.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.77 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.83 | 1.6% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $15.62 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $997.17 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $209.55 | 8 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $206.00 | 31 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $144.98 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $110.27 | 6 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $108.11 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $80.82 | 4 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $31.61 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $9.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 275 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 214 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 45 |
| Donepezil Hcl | Donepezil Hcl | 153 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 47 |
| Losartan Potassium | Losartan Potassium | 125 | 35 |
| Eliquis | Apixaban | 117 | 29 |
| Sertraline Hcl | Sertraline Hcl | 116 | 42 |
| Furosemide | Furosemide | 115 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 32 |
| Memantine Hcl | Memantine Hcl | 100 | 42 |
| Mirtazapine | Mirtazapine | 87 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 33 |
| Metformin Hcl | Metformin Hcl | 72 | 24 |
| Gabapentin | Gabapentin | 67 | 26 |
| Simvastatin | Simvastatin | 66 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 15 |
| Lisinopril | Lisinopril | 61 | 17 |
| Divalproex Sodium | Divalproex Sodium | 52 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 15 |
| Montelukast Sodium | Montelukast Sodium | 47 | 11 |
| Myrbetriq | Mirabegron | 46 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Alprazolam | Alprazolam | 38 | 18 |
| Omeprazole | Omeprazole | 37 | 12 |
| Allopurinol | Allopurinol | 36 | 13 |
| Carvedilol | Carvedilol | 36 | 16 |
| Tramadol Hcl | Tramadol Hcl | 34 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 12 |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Famotidine | Famotidine | 28 | 13 |
| Trazodone Hcl | Trazodone Hcl | 27 | 17 |
| Cephalexin | Cephalexin | 26 | 25 |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Finasteride | Finasteride | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Nystatin | Nystatin | 14 | suppressed |
| Prednisone | Prednisone | 14 | 11 |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $997.17 · 70 records | Sumitomo Pharma America, Inc. | CAPVAXIVE, GEMTESA, KISUNLA, LEQEMBI, MYFEMBREE, PRECIVITYAD2, REXULTI, VRAYLAR, XIFAXAN, YUPELRI, ZENPEP | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error